CHO-K1/Human RXFP1 Stable Cell
Item | Cat# | Price |
Stable Cell Line | SNB-G-0208A | $19,800 |
Compound Testing Services | CT-001 | $1,850 per 384w plate (Up To 16 cpds Dose) |
Product Description
The RXFP1 receptor (relaxin family peptide receptor 1), also known as LGR7, is a multi-domain G protein-coupled receptor containing leucine-rich repeats and an LDLa module . It is widely distributed in various human tissues including the brain (e.g., amygdala, thalamus), kidneys (particularly glomerular endothelial cells), heart, lungs, liver, and reproductive organs (uterus, ovaries, testis). Its core function, upon activation by its endogenous ligand relaxin-2, primarily involves stimulating cAMP production via Gs proteins, thereby mediating key effects such as vasodilation, anti-fibrosis, anti-inflammation, angiogenesis, and renal hemodynamic regulation. Consequently, RXFP1 holds potential as a therapeutic target for cardiovascular protection, renal function regulation, and fibrotic diseases.
Screeningbio’s CHO-K1/Human RXFP1 cell line overexpress RXFP1 and is designed to detect increases in intracellular cAMP levels in response to agonist stimulation of the receptor. Cisbio HTRF cAMP kit can be used to detect the signal.
Product Specifications
Target Type | GPCR |
Species | Human |
HGNC Symbol | RXFP1 |
Accession Number | NM_021634 |
Parental Line | CHO-K1 |
Lot# | See Vial |
Storage | Liquid Nitrogen |
Data
Target Background
The RXFP1 receptor (relaxin family peptide receptor 1), also known as LGR7, is a multi-domain G protein-coupled receptor containing leucine-rich repeats and an LDLa module .
It is widely distributed in various human tissues including the brain (e.g., amygdala, thalamus), kidneys (particularly glomerular endothelial cells), heart, lungs, liver, and reproductive organs (uterus, ovaries, testis). Its core function, upon activation by its endogenous ligand relaxin-2, primarily involves stimulating cAMP production via Gs proteins, thereby mediating key effects such as vasodilation, anti-fibrosis, anti-inflammation, angiogenesis, and renal hemodynamic regulation.
Consequently, RXFP1 holds potential as a therapeutic target for cardiovascular protection, renal function regulation, and fibrotic diseases.